Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial

INTRODUCTION: Kidney stones are a global healthcare problem. Given high recurrence rates and the morbidity associated with symptomatic stone disease, effective medical prophylaxis is clearly an unmet need. Explanatory analyses of randomised controlled trials with sodium/glucose cotransporter isoform...

Descripción completa

Detalles Bibliográficos
Autores principales: Schietzel, Simeon, Bally, Lia, Cereghetti, Grazia, Faller, Nicolas, Moor, Matthias B, Vogt, Bruno, Rintelen, Felix, Trelle, S, Fuster, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921923/
https://www.ncbi.nlm.nih.gov/pubmed/35288397
http://dx.doi.org/10.1136/bmjopen-2021-059073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921923/
https://www.ncbi.nlm.nih.gov/pubmed/35288397
http://dx.doi.org/10.1136/bmjopen-2021-059073

Ejemplares similares